Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ida Paris

Showing results (91-100 of 100) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 100 results.
NPJ Breast Cancer|May 29, 2026
Platinum-based neoadjuvant chemotherapy and the predictive role of DNA damage response biomarkers in TNBC: the NeoCarbo studyEriseld Krasniqi, Anna Di Benedetto, Lorena Filomeno, et al.
Cancer Biology & Therapy|November 8, 2018
A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer StudyTeresa Gamucci, Laura Pizzuti, Clara Natoli, et al.
Journal of Experimental & Clinical Cancer Research : CR|December 11, 2020
Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER StudyGiulia Bon, Laura Pizzuti, Valentina Laquintana, et al.
Scientific Reports|July 3, 2021
The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trialLaura Pizzuti, Maddalena Barba, Marco Mazzotta, et al.
Cancers|December 17, 2024
Tolerability and Preliminary Outcomes of Adjuvant T-DM1 in HER2-Positive Breast Cancer After Neoadjuvant Therapy: The ATD StudyEriseld Krasniqi, Lorena Filomeno, Teresa Arcuri, et al.
Journal of Cellular Physiology|December 12, 2018
Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experienceLaura Pizzuti, Antonio Giordano, Andrea Michelotti, et al.
Journal of Cellular Physiology|January 17, 2020
Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidenceEriseld Krasniqi, Laura Pizzuti, Giacomo Barchiesi, et al.
Therapeutic Advances in Medical Oncology|February 17, 2022
PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world settingLaura Pizzuti, Eriseld Krasniqi, Isabella Sperduti, et al.
Frontiers in Oncology|June 1, 2023
Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from <i>CaRe</i>, a multicentric, observational studyFrancesca Sofia Di Lisa, Eriseld Krasniqi, Laura Pizzuti, et al.
International Journal of Cancer|July 23, 2019
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world settingLaura Pizzuti, Eriseld Krasniqi, Giacomo Barchiesi, et al.
Pageof 10

Showing results (91-100 of 100) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 100 results.
NPJ Breast Cancer|May 29, 2026
Platinum-based neoadjuvant chemotherapy and the predictive role of DNA damage response biomarkers in TNBC: the NeoCarbo studyEriseld Krasniqi, Anna Di Benedetto, Lorena Filomeno, et al.
Cancer Biology & Therapy|November 8, 2018
A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer StudyTeresa Gamucci, Laura Pizzuti, Clara Natoli, et al.
Journal of Experimental & Clinical Cancer Research : CR|December 11, 2020
Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER StudyGiulia Bon, Laura Pizzuti, Valentina Laquintana, et al.
Scientific Reports|July 3, 2021
The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trialLaura Pizzuti, Maddalena Barba, Marco Mazzotta, et al.
Cancers|December 17, 2024
Tolerability and Preliminary Outcomes of Adjuvant T-DM1 in HER2-Positive Breast Cancer After Neoadjuvant Therapy: The ATD StudyEriseld Krasniqi, Lorena Filomeno, Teresa Arcuri, et al.
Journal of Cellular Physiology|December 12, 2018
Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experienceLaura Pizzuti, Antonio Giordano, Andrea Michelotti, et al.
Journal of Cellular Physiology|January 17, 2020
Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidenceEriseld Krasniqi, Laura Pizzuti, Giacomo Barchiesi, et al.
Therapeutic Advances in Medical Oncology|February 17, 2022
PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world settingLaura Pizzuti, Eriseld Krasniqi, Isabella Sperduti, et al.
Frontiers in Oncology|June 1, 2023
Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from <i>CaRe</i>, a multicentric, observational studyFrancesca Sofia Di Lisa, Eriseld Krasniqi, Laura Pizzuti, et al.
International Journal of Cancer|July 23, 2019
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world settingLaura Pizzuti, Eriseld Krasniqi, Giacomo Barchiesi, et al.
Pageof 10